Cambridge Investment Research Advisors’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $423K | Sell |
5,405
-248
| -4% | -$16.9K | ﹤0.01% | 3123 |
|
|
2026
Q1 | $365K | Sell |
5,653
-1,763
| -24% | -$124K | ﹤0.01% | 3098 |
|
|
2025
Q4 | $499K | Buy |
7,416
+366
| +5% | +$24.6K | ﹤0.01% | 2719 |
|
|
2025
Q3 | $517K | Buy |
7,050
+43
| +0.6% | +$2.86K | ﹤0.01% | 2649 |
|
|
2025
Q2 | $365K | Buy |
7,007
+131
| +2% | +$7.45K | ﹤0.01% | 2817 |
|
|
2025
Q1 | $439K | Sell |
6,876
-155
| -2% | -$9K | ﹤0.01% | 2556 |
|
|
2024
Q4 | $336K | Sell |
7,031
-2,530
| -26% | -$130K | ﹤0.01% | 2750 |
|
|
2024
Q3 | $547K | Buy |
9,561
+2,547
| +36% | +$146K | ﹤0.01% | 2335 |
|
|
2024
Q2 | $367K | Sell |
7,014
-354
| -5% | -$15.5K | ﹤0.01% | 2550 |
|
|
2024
Q1 | $300K | Sell |
7,368
-698
| -9% | -$26.2K | ﹤0.01% | 2703 |
|
|
2023
Q4 | $298K | Buy |
8,066
+832
| +12% | +$31.3K | ﹤0.01% | 2600 |
|
|
2023
Q3 | $276K | Buy |
7,234
+16
| +0.2% | +$655 | ﹤0.01% | 2557 |
|
|
2023
Q2 | $260K | Sell |
7,218
-901
| -11% | -$30.7K | ﹤0.01% | 2662 |
|
|
2023
Q1 | $310K | Sell |
8,119
-356
| -4% | -$16.7K | ﹤0.01% | 2461 |
|
|
2022
Q4 | $482K | Sell |
8,475
-505
| -6% | -$25.9K | ﹤0.01% | 2042 |
|
|
2022
Q3 | $355K | Buy |
8,980
+1,218
| +16% | +$53.8K | ﹤0.01% | 2233 |
|
|
2022
Q2 | $342K | Buy |
7,762
+200
| +3% | +$8.65K | ﹤0.01% | 2264 |
|
|
2022
Q1 | $302K | Sell |
7,562
-372
| -5% | -$13.3K | ﹤0.01% | 2549 |
|
|
2021
Q4 | $319K | Buy |
7,934
+1,128
| +17% | +$42.1K | ﹤0.01% | 2476 |
|
|
2021
Q3 | $277K | Buy |
6,806
+1,588
| +30% | +$66.4K | ﹤0.01% | 2527 |
|
|
2021
Q2 | $237K | Sell |
5,218
-939
| -15% | -$41.6K | ﹤0.01% | 2672 |
|
|
2021
Q1 | $257K | Buy |
6,157
+23
| +0.4% | +$1.05K | ﹤0.01% | 2404 |
|
|
2020
Q4 | $262K | Buy |
+6,134
| New | +$220K | ﹤0.01% | 2255 |
|
|
2020
Q3 | – | Sell |
-9,435
| Closed | -$253K | – | 2557 |
|
|
2020
Q2 | $253K | Buy |
+9,435
| New | +$213K | ﹤0.01% | 2021 |
|
|
2020
Q1 | – | Sell |
-10,483
| Closed | -$186K | – | 2358 |
|
|
2019
Q4 | $186K | Sell |
10,483
-99
| -0.9% | -$1.72K | ﹤0.01% | 2236 |
|
|
2019
Q3 | $164K | Sell |
10,582
-600
| -5% | -$9.88K | ﹤0.01% | 2162 |
|
|
2019
Q2 | $192K | Sell |
11,182
-500
| -4% | -$8.07K | ﹤0.01% | 2008 |
|
|
2019
Q1 | $188K | Buy |
11,682
+382
| +3% | +$6.19K | ﹤0.01% | 2085 |
|
|
2018
Q4 | $165K | Hold |
11,300
| – | – | ﹤0.01% | 1967 |
|
|
2018
Q3 | $205K | Buy |
+11,300
| New | +$198K | ﹤0.01% | 2042 |
|
Other funds holding HALO
Cambridge Investment Research Advisors's HALO Position: Q2 2026 in Review
Cambridge Investment Research Advisors reduced its Halozyme (HALO) stake by 4.4% in Q2 2026, selling an estimated $16.9K and leaving 5,405 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #3123.
Cambridge Investment Research Advisors first reported a position in HALO in Q3 2018 and has held it in 30 quarters since. The position peaked at $547K in Q3 2024. 675 funds tracked by Wall St. Rank hold HALO as of Q2 2026.
- Cambridge Investment Research Advisors held 5,405 shares of Halozyme worth $423K as of Q2 2026.
- Cambridge Investment Research Advisors sold 248 Halozyme shares in Q2 2026, an estimated $16.9K.
- Halozyme made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3123 holding.
- Cambridge Investment Research Advisors first reported a position in Halozyme in Q3 2018 and has held it in 30 quarters since.
- Cambridge Investment Research Advisors's Halozyme position peaked at $547K in Q3 2024.
- 675 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.